The stock is still trading like a financing story rather than an operating one: the market is discounting future dilution more heavily than current growth. That setup can work both ways in a low-float name with high short interest — a clean quarter or two can trigger a sharp cover rally over days to weeks — but only if management proves it can get through the next 1-2 quarters without tapping equity.

The backlog and pipeline matter less as headline size than as evidence that customer demand is real enough to support a cash conversion inflection. In acquisition-led rollups, reported growth often comes with weaker gross margin and more working-capital drag, so the key second-order question is whether this becomes a self-funded scale story or a perpetual dilution machine. If the former, peers with weaker balance sheets should see multiple compression; if the latter, the market will keep valuing this at an option price.

Contrarian view: consensus may be overfocusing on warrant/dilution overhang and underpricing reflexive upside from short covering if the next two prints show margin stabilization. But the structural re-rate is a 6-18 month path, not an immediate one, and it dies quickly if financing shows up, margins roll over again, or backlog fails to convert into operating cash. Those are the clean falsifiers to watch.